NCT05040906Unknown3 期
A Phase 3, Randomized, Double-blind Study of H02 Plus CHOP Versus R-CHOP in Patients With Diffuse Large B-cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 416
- 试验地点
- 1
- 主要终点
- ORR(based on the evaluation of the IRC)
研究概览
简要总结
This trial is a Multicenter, randomized, double-blind, parallel, controlled, and equivalence phase Ⅲ study.
Primary objective:
The purpose is to compare the objective response rate of H02 (rituximab biosimilar) plus CHOP and rituximab plus CHOP, as first-line treatment of diffuse large B-cell lymphoma.
Secondary objective:
The purpose is to compare the safety of H02 combined with CHOP regimen and rituximab injection (Rituximab®) combined with CHOP regimen in the treatment of newly treated diffuse large B-cell lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Untreated CD20-positive DLBCL confirmed.
- •18 years to 75 years; Male or female patients.
- •IPI score of 1 to 2 and an ECOG performance status of 0 to
- •More than 6 months life expectancy.
- •At least one measurable lymph node:
- •For intranodal lesions, equal or greater than 1.5 cm in the long axis and equal or greater than 1.0 cm in the short diameter; For extranodal lesions, equal or greater than 1.0 cm in the long axis.
- •Adequate cardiac function (LVEF≥50%).
- •Absolute neutrophil count(ANC) ≥1.5*109/L and platelet count(PLT) ≥75*109/L and hemoglobin ≥75g/L, total bilirubin level ≤1.5×upper limit of normal (ULN), aspartic acid Aminotransferase (AST), alanine aminotransferase (ALT)≤2.5×ULN, creatinine level (Cr)≤1.5×ULN.
- •Signed an informed consent form which was approved by the institutional review board of the respective medical center.
- •Exclusion Criteria
- •Primary central nervous system(CNS) lymphoma, secondary CNS involvement, primary skin DLBCL (leg type), primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, and primary exudation Lymphoma, T-cell/histiocytosis-rich large B-cell lymphoma, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, lymphoma-like granuloma, EBV-positive mucosal skin ulcer, HHV8+DLBCL, NOS, primary testicular lymphomas.
- •High-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangement diagnosed by fluorescence in situ hybridization (FISH).
- •B-cell lymphoma has characteristics between DLBCL and classic HL, and cannot be divided into types.
- •Transformed lymphoma. those who have transformed from other types of lymphomas, such as follicular lymphoma, marginal zone B-cell lymphoma, and chronic lymphocytic leukemia/small B-cell lymphoma.
- •History of other malignancy, except for skin basal cell carcinoma and cervical carcinoma in situ and has been in remission without treatment for >/= 5 years prior to enrolment.
- •Severe mental illness.
- •Positive for HIV infection.
- •Positive for HCV infection.
- •Patients who have HBV (+) are eligible.
- •History of anti-CD20 monoclonal antibody treatment for other disease (e.g., rheumatoid arthritis).
- •Previous treatment for NHL, including chemotherapy, immunotherapy, radiotherapy, monoclonal antibody therapy or surgical treatment (except lymph node biopsies diagnostic surgery and biopsy).
- •Participation in another clinical trial in the past 3 months.
- •Vaccination with a attenuated live vaccine within 4 weeks.
- •Use of hemopoietic cytokine in the past 2 weeks, e.g. granulocyte colony stimulating factor(G-CSF).
- •Disease or symptom by the investigator's discretion(interstitial pneumonia, Uncontrollable systemic infections,severe cardiovascular disease (New York Heart Association functional class III or IV, myocardial infarction or unstable arrhythmia or unstable angina in the last 6 months, severe cardiac insufficiency, rogressive multifocal leukoencephalopathy), uncontrolled hypertension (SBP≥180mmHg and/or DBP≥100mmHg), active autoimmune diseases)
- •Known hypersensitivity to any of the study drugs or its ingredients.
- •Prior treatment with anthracycline.
- •DLBCL invaded by special parts such as testis, breast, ovary, etc.
- •Pregnant or lactating women.
- •The researcher believes that it is not suitable for enrollment.
排除标准
- 未提供
研究组 & 干预措施
H02+ Chemotherapy
Experimental
Participants received six cycles of H02(375 mg/m2) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).
干预措施: H02+CHOP (Drug)
Rituxan+Chemotherapy
Active Comparator
Participants received six cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
干预措施: Rituxan +CHOP (Drug)
结局指标
主要结局
ORR(based on the evaluation of the IRC)
时间窗: 18 weeks
To evaluate the objective response rate (ORR) in patients with previously untreated Diffuse Large B-cell Lymphoma after six periods of treatment.
次要结局
- Complete response (CR) rate (based on the evaluation of the IRC and investigator)(18 weeks)
- ORR(based on the judgment of the investigator)(18 weeks)
- 1-year progression-free survival (PFS) rate(1 year)
- Duration of remission within 1 year (DOR)(1 year)
- 1-year overall survival (OS) rate(1 year)
- 1-year event-free survival (EFS) rate(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)Metastatic Colorectal CancerNCT04547166Shanghai Henlius Biotech568
已完成
3 期
Study to Investigate CSL112 in Subjects With Acute Coronary SyndromeAcute Coronary SyndromeNCT03473223CSL Behring18,226
已完成
3 期
Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose IntoleranceLactose IntoleranceNCT03597516Ritter Pharmaceuticals, Inc.557
已完成
3 期
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) InhibitorsUlcerative ColitisNCT02136069Hoffmann-La Roche397
进行中（未招募）
3 期
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)Multiple SclerosisNCT04544436Hoffmann-La Roche864